Literature DB >> 18388521

Immunization of patients with rheumatoid arthritis with antitumor necrosis factor alpha therapy and methotrexate.

Hans-Peter Brezinschek1, Thomas Hofstaetter, Burkhard F Leeb, Pia Haindl, Winfried B Graninger.   

Abstract

PURPOSE OF REVIEW: The aim of this study is to highlight the recent findings on the use of methotrexate and/or TNFalpha-blockers in adult patients with rheumatoid arthritis and their effects on the immune response to various vaccines. RECENT
FINDINGS: Regarding influenza vaccination, methotrexate monotherapy is not associated with a decreased response, whereas the use of etanercept and infliximab in combination with methotrexate may cause lower titers and lower response rates. Concerning pneumococcal vaccination, methotrexate seems to impair responsiveness. The concomitant use of adalimumab and methotrexate is also associated with decreased response, whereas the concomitant use of etanercept or infliximab seems not to have an effect on response rates. As immunological pathways seem to play a major role, T-cell-dependent pneumococcal vaccines are designed to achieve higher response rates and protective titers.
SUMMARY: Patients with rheumatic disorders are more likely to develop preventable infectious diseases, which underlines the importance of adequate immunoprotective titers. Several studies have shown that the combination of methotrexate and certain TNFalpha-blockers are affecting the responsiveness to vaccines. Further findings indicate that the response also depends on what type of vaccine is used.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18388521     DOI: 10.1097/BOR.0b013e3282ffdeca

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  12 in total

1.  Routinely measuring and reporting pneumococcal vaccination among immunosuppressed rheumatology outpatients: the first step in improving quality.

Authors:  Sonali P Desai; Alexander Turchin; Lara E Szent-Gyorgyi; Michael Weinblatt; Jonathan Coblyn; Daniel H Solomon; Allen Kachalia
Journal:  Rheumatology (Oxford)       Date:  2010-10-24       Impact factor: 7.580

Review 2.  Preventing infective complications in inflammatory bowel disease.

Authors:  Justine Mill; Ian C Lawrance
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 3.  Vaccination strategies in patients with IBD.

Authors:  Javier P Gisbert; María Chaparro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-02-19       Impact factor: 46.802

Review 4.  Clinical application and evaluation of anti-TNF-alpha agents for the treatment of rheumatoid arthritis.

Authors:  Juan Jin; Yan Chang; Wei Wei
Journal:  Acta Pharmacol Sin       Date:  2010-08-16       Impact factor: 6.150

Review 5.  [Biological therapy for the treatment of rheumatic diseases].

Authors:  M Pierer; C Baerwald
Journal:  Internist (Berl)       Date:  2008-08       Impact factor: 0.743

Review 6.  Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis.

Authors:  Alejandro Díaz-Borjón
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

7.  Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus.

Authors:  Kiyoshi Migita; Yukihiro Akeda; Manabu Akazawa; Shigeto Tohma; Fuminori Hirano; Haruko Ideguchi; Ryutaro Matsumura; Eiichi Suematsu; Tomoya Miyamura; Shunsuke Mori; Takahiro Fukui; Yasumori Izumi; Nozomi Iwanaga; Hiroshi Tsutani; Kouichirou Saisyo; Takao Yamanaka; Shiro Ohshima; Takao Sugiyama; Yojiro Kawabe; Masao Katayama; Yasuo Suenaga; Akira Okamoto; Hisaji Ohshima; Yasumasa Okada; Kenji Ichikawa; Shigeru Yoshizawa; Kenji Kawakami; Toshihiro Matsui; Hiroshi Furukawa; Kazunori Oishi
Journal:  Arthritis Res Ther       Date:  2015-06-03       Impact factor: 5.156

8.  Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases--a longitudinal study.

Authors:  Lara Fischer; Patricia Francis Gerstel; Antoine Poncet; Claire-Anne Siegrist; Emmanuel Laffitte; Cem Gabay; Joerg Dieter Seebach; Camillo Ribi
Journal:  Arthritis Res Ther       Date:  2015-06-06       Impact factor: 5.156

9.  Boi-ogi-to (TJ-20), a Kampo Formula, Suppresses the Inflammatory Bone Destruction and the Expression of Cytokines in the Synovia of Ankle Joints of Adjuvant Arthritic Rats.

Authors:  Xinwen Zhang; Zhou Wu; Yicong Liu; Junjun Ni; Chunfu Deng; Baohong Zhao; Hiroshi Nakanishi; Jing He; Xu Yan
Journal:  Evid Based Complement Alternat Med       Date:  2017-05-07       Impact factor: 2.629

10.  Opsonic and Antibody Responses to Pneumococcal Polysaccharide in Rheumatoid Arthritis Patients Receiving Golimumab Plus Methotrexate.

Authors:  Kiyoshi Migita; Yukihiro Akeda; Manabu Akazawa; Shigeto Tohma; Fuminori Hirano; Haruko Ideguchi; Ryutaro Matsumura; Eiichi Suematsu; Tomoya Miyamura; Shunsuke Mori; Takahiro Fukui; Yasumori Izumi; Nozomi Iwanaga; Yuka Jiuchi; Hideko Kozuru; Hiroshi Tsutani; Kouichirou Saisyo; Takao Yamanaka; Shiro Ohshima; Naoya Mori; Akinori Matsumori; Kiyoki Kitagawa; Koichiro Takahi; Tetsuo Ozawa; Norikazu Hamada; Kyoichi Nakajima; Hideaki Nagai; Norio Tamura; Yasuo Suenaga; Masaharu Kawabata; Toshihiro Matsui; Hiroshi Furukawa; Kenji Kawakami; Kazunori Oishi
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.